Recent studies on retatrutides, a dual agonist for incretin hormone and gastric inhibitory polypeptide, suggest promising findings in treating obesity and type 2 diabetic condition. Early evidence from clinical experiments show substantial read more reductions in body mass and bettered glucose regulation. Further research is focused on long-term ha